Home › Myeloproliferative Neoplasms › South Carolina
Pag-aaral pangklinika para sa Myeloproliferative Neoplasms sa South Carolina
5 pag-aaral para sa Myeloproliferative Neoplasms ang naghahanap ng mga kalahok sa mga site sa South Carolina.
Mga Lungsod sa South Carolina
Opisyal na teksto ng pag-aaral (English)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Medical University of South Carolina, Charleston
- Prisma Health Cancer Institute - Easley, Easley
- at 5 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05564390Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Medical University of South Carolina, Charleston
- Prisma Health Cancer Institute - Easley, Easley
- at 5 pa
Nagre-recruitPhase 2
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT05554406(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- MUSC Health University Medical Center, Charleston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04996875Project: Every Child for Younger Patients With Cancer
- Medical University of South Carolina, Charleston
- Prisma Health Richland Hospital, Columbia
- BI-LO Charities Children's Cancer Center, Greenville
- at 2 pa
Nagre-recruitObservasyonal na pag-aaral
Hanggang edad 25 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT02402244SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Greenville
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.